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Mitochondrial Genetics And Stroke Recovery 
Steven C Cramer, Univ of California, Irvine, Irvine, CA; Vincent Procaccio, UC Irvine, Irvine, 
CA; the GAIN Americas and GAIN International Study investigators 
Introduction: Spontaneous recovery after stroke is variable and incomplete. Some of this 
variability might arise from genetic factors. We previously described a significant association 
between poorer stroke recovery and presence of either BDNF val66met or ApoE4 poly­
morphism. Another set of genetic factors of potential interest pertains to mitochondrial 
haplotype. Variation in mitochondrial haplotype is important to cellular energy metabolism and 
thus potentially to brain reformatting after stroke, and has significant clinical associations e.g., 
increased longevity and risk of degenerative disease. The current study examined the 
hypothesis that variation in mitochondrial DNA (mtDNA) haplotype is associated with degree of 
recovery from stroke. Methods: This study examined data from 241 patients from the Glycine 
Antagonist In Neuroprotection (GAIN) studies. Inclusion criteria included treatment star1ed 
within 6 hr of stroke symptom onset, age > = 18 yr, and limb weakness. Determination of 
mtDNA haplotype in stored blood samples was carried out by analysis of the hypervariable 
sequences of the non-coding region and by PCR-RFLP of the mtDNA. Behavioral data acquired 
during the trial were used to evaluate recovery in relation to genotype. The primary endpoint 
was change in the NIH Stroke Scale (NIHSS) score from acute to 1 month after stroke, with 
secondary endpoints examining change to 3 months post-stroke as well as change in modified 
Rankin Scale (mRS) and Barthel Index (Bl). NIHSS was assessed acutely (immediately prior to 
treatment) as well as 1 and 3 months post-stroke; mRS was estimated pre-stroke then 
assessed 1 month and 3 months post-stroke; Bl was assessed 1 week, 1 month, and 3 months 
post-stroke. Results: Sufficient DNA was available to determine the mtDNA haplotype in 
227/241 subjects. Across the 6 mtDNA haplotypes, Kruskal-Wallis testing did not find a 
difference in relation to change in the primary endpoint or in any of the secondary endpoints. 
When each of the 6 haplotypes was examined separately, results suggested an effect of one 
haplotype: subjects with the RO mtDNA haplotype (n = 102) had a higher change in the primary 
endpoint compared to subjects (n = 125) without the RO mtDNA haplotype (median improve­
ment in NIHSS score from acute to 1 month post-stroke 5 vs. 4 points, P<0.005, Wilcoxon 
Rank Sums test). Conclusions: Mitochondria generate cellular energy as well as reactive 
oxygen species. Variation in mttochondrial genetics might therefore influence recovery from 
stroke, a possibility suggested by the association that genetic variability in other pathways has 
with recovery from stroke in human subjects. The current findings suggest this might be true 
in relation to the RO mtDNA haplotype. These findings might be of value to stroke trials, for 
example for stratification, and might suggest future avenues for treatment strategies according 
to individual genotype. 
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